A B-cell targeted therapy repurposed from treatment of leukaemia and rheumatoid arthritis is showing promise in treating patients with relapsing multiple sclerosis. The anti CD-20 monoclonal antibody ofatumumab significantly reduced new inflammation and resulted in fewer clinical relapses and progressive events, say researchers who compared the safety and efficacy of the immune modulating drug with ...
Positive results for B-cell targeted therapy in MS
By Sunalie Silva
12 Aug 2020